GRPS · Trans American Aquaculture, Inc · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These factors, as relative to capital raising activities, create doubt as to our ability to continue as a going concern.”View the 10-Q filed Jan 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| $16.5K | $331.65K | $101.57K | $49K | $316.11K | — | |
| -$148.79K | $321.62K | $661.59K | $287.13K | $973.42K | — | |
| $165.29K | $10.03K | -$560.02K | -$238.13K | -$657.31K | — | |
| — | 3.02% | -551.34% | -485.97% | -207.93% | — | |
| $599.79K | $846.23K | $864.77K | $148.61K | $232.43K | — | |
| — | $52.29K | $55.59K | — | — | — | |
| $249K | $477.96K | $490.05K | $485.45K | $544.54K | — | |
| -$1.7M | -$1.97M | -$497.14K | -$509.14K | -$512.1K | — | |
| -$2.13M | -$2.81M | -$1.92M | -$895.88K | -$1.4M | $155.2K | |
| $0 | $0 | -$26.94K | $26.94K | $0 | — | |
| -$2.15M | -$2.81M | -$1.89M | -$922.82K | -$1.4M | — | |
| — | -846.96% | -1865.63% | -1883.26% | -443.46% | — | |
| USD/shares | -$0.00 | -$0.00 | -$0.00 | -$0.00 | $0.00 | — |
| USD/shares | -$0.00 | -$0.00 | -$0.00 | -$0.00 | $0.00 | — |
| shares | — | 1.81B | 1.45B | 1.29B | 0 | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2024: $0 in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Bank overdrafts | 2025-09-30 | USD 0 | 10-Q filed 2026-01-14 |
| Notes payable, including current maturities | 2025-09-30 | USD 616,528 | 10-Q filed 2026-01-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 16 similar-size Drug Manufacturers - Specialty & Generic companies (of 109 listed).